Cytek BioSciences Profit Margin

Cytek BioSciences (CTKB) currently reports a profit margin of -38.98% as of June 2026. That compares with -3.27% in the prior-year period — down 1093.8% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Cytek BioSciences's profit margin history and peer comparisons.

Cytek BioSciences's profit margin decreased from -3.27% to -38.98% — a 1093.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cytek BioSciences's profit margin of -38.98% is lower than the Healthcare sector average of 13.89%. That is roughly 380.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cytek BioSciences's current -38.98% should be judged against Healthcare norms (sector average: 13.89%) and against CTKB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -38.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Cytek BioSciences, and consider following CTKB for alerts when major investors trade the stock.